T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$2.06 USD
-0.13 (-5.94%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $2.06 0.00 (0.00%) 5:56 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for T2 Biosystems, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 16 | 10 | 32 | 42 | 11 |
Receivables | 1 | 2 | 5 | 5 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 4 | 4 | 4 | 4 |
Other Current Assets | 3 | 3 | 3 | 3 | 1 |
Total Current Assets | 25 | 19 | 44 | 54 | 19 |
Net Property & Equipment | 2 | 5 | 5 | 4 | 6 |
Investments & Advances | 0 | 0 | 0 | 10 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 2 | 2 | 1 | 0 |
Total Assets | 35 | 34 | 61 | 79 | 28 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 41 | 0 | 0 | 0 | 43 |
Accounts Payable | 2 | 1 | 3 | 2 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 7 | 8 | 8 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 1 | 0 | 3 |
Total Current Liabilities | 56 | 10 | 12 | 10 | 61 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 50 | 48 | 45 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 6 | 5 | 4 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 63 | 74 | 73 | 70 | 62 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 556 | 495 | 459 | 432 | 342 |
Retained Earnings | -584 | -534 | -472 | -423 | -376 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -28 | -40 | -13 | 9 | -34 |
Total Liabilities & Shareholder's Equity | 35 | 34 | 61 | 79 | 28 |
Total Common Equity | -28 | -40 | -13 | 9 | -34 |
Shares Outstanding | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | -7.01 | -39.66 | -12.90 | 8.73 | -34.01 |
Fiscal Year End for T2 Biosystems, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 6 | 16 | 24 | 16 |
Receivables | 1 | 2 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 5 | 5 | 4 | 4 |
Other Current Assets | 2 | 3 | 3 | 3 | 2 |
Total Current Assets | 13 | 16 | 25 | 33 | 24 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 22 | 25 | 35 | 43 | 37 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 12 | 42 | 41 | 41 | 51 |
Accounts Payable | 2 | 2 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 9 | 10 | 10 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 2 | 1 |
Total Current Liabilities | 22 | 56 | 56 | 55 | 66 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 63 | 63 | 63 | 74 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 601 | 560 | 556 | 555 | 522 |
Retained Earnings | -607 | -598 | -584 | -574 | -559 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -6 | -38 | -28 | -19 | -36 |
Total Liabilities & Shareholder's Equity | 22 | 25 | 35 | 43 | 37 |
Total Common Equity | -6 | -38 | -28 | -19 | -36 |
Shares Outstanding | 17.30 | 5.50 | 4.00 | 3.90 | 2.90 |
Book Value Per Share | -0.34 | -6.87 | -7.01 | -4.93 | -12.56 |